After two difficult years, the numbers in US biopharma hiring have turned. BioSpace, which tracks workforce cuts across the industry, recorded 27 biopharma companies making or planning layoffs in the third quarter of 2026, affecting around 2,568 people. Both figures are the lowest quarterly totals since it began tracking in 2024.
The quarter before told the same story from the other side. In Q2 2026, BioSpace reported job postings up 15% year on year, the third quarterly increase in a row, while the number of companies cutting staff fell sharply.
Why a recovering market is harder to hire in
When layoffs are high, good people are available and searches move quickly. As cuts slow, that pool shrinks. The professionals who kept their jobs through 2024 and 2025 are now the people hiring managers want, and most of them are employed, cautious and in no hurry to move.
Candidate caution shows up in the data too. In the survey behind BioSpace's 2026 Employment Outlook, 64% of employed and contract professionals said they would actively look for a new role in 2026. Looking is not moving: people who have lived through restructuring want a strong reason to change jobs.
A split market
Sentiment is not uniform. Endpoints' Q3 2026 biopharma sentiment survey, reported by Knight Frank, found 52% of biotech respondents expecting headcount growth, while 44% of big pharma respondents expected cuts. Smaller, funded companies are building teams while large organisations keep trimming, so the same specialists are being approached by several growing employers at once.
What it means for hiring managers
- Expect to compete for people who are not looking. Advertising alone reaches the minority of candidates who are actively applying.
- Lead with the reason to move. Progression, schedule, technology and stability matter more to cautious candidates than a job title.
- Move quickly once you find them. Strong candidates in a tightening market rarely run a single process.
Sources: BioSpace, Q3 layoffs report. BioSpace, Q2 2026 job market report. BioSpace, 2026 Employment Outlook survey. Knight Frank, UK Science and Innovation Insight Q3 2026.